A phase 1 open-label trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of subcutaneous VIS171 in participants with autoimmune disease(s).

ENSAYO CLÍNICO CON MEDICAMENTOS